What caused MCK's earnings volatility in 2025?

McKesson Corporation's earnings volatility in 2025 can be attributed to several key factors:

1. **Acquisitions and Divestitures**: McKesson's acquisition of a controlling interest in Florida Cancer Specialists & Research Institute’s Core Ventures in 2025 is expected to enhance its integrated oncology platform and contribute to its long-term growth. However, such significant acquisitions can lead to short-term volatility as the company integrates the acquired businesses into its operations. Additionally, the divestiture of its Canada-based Rexall and Well.ca businesses may have impacted its earnings in the period leading up to the sale.
2. **Market Conditions and Competition**: The pharmaceutical and healthcare sectors are highly competitive and subject to various market dynamics, including regulatory changes, pricing pressures, and market trends. These factors can influence McKesson's earnings and profitability over any given period.

In conclusion, McKesson's 2025 earnings volatility is primarily due to the impact of acquisitions and divestitures on its financial performance, as well as the broader market conditions and competitive landscape in which it operates.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|MCK|MCK.N|McKesson|2025 Q1|-3.711133400200602|9.6E8|169|
|MCK|MCK.N|McKesson|2025 Q2|-59.17496443812234|2.87E8|169|
|MCK|MCK.N|McKesson|2025 Q3|47.3015873015873|9.28E8|169|